Redhill Biopharma Ltd. - American Depositary Shares (RDHL)
2.1600
-0.0600 (-2.70%)
NASDAQ · Last Trade: Oct 3rd, 10:59 AM EDT
Detailed Quote
Previous Close
2.220
Open
2.190
Bid
2.160
Ask
2.170
Day's Range
2.160 - 2.260
52 Week Range
1.060 - 9.000
Volume
46,308
Market Cap
-
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
N/A (N/A)
1 Month Average Volume
2,535,836
Chart
About Redhill Biopharma Ltd. - American Depositary Shares (RDHL)
Redhill Biopharma is a biopharmaceutical company focused on the development and commercialization of innovative therapies for gastrointestinal diseases and other serious conditions. The company specializes in creating novel formulations and repurposing existing drugs to improve treatment outcomes for patients. Redhill is dedicated to addressing unmet medical needs through its robust pipeline of products, which includes both clinical-stage candidates and marketed drugs. By leveraging advanced scientific research and a strategic approach to drug development, Redhill aims to improve the lives of patients suffering from complex health issues. Read More
Gainers Dogwood Therapeutics (NASDAQ: DWTX) stock moved upwards by 80.1% to $9.94 during Monday's pre-market session. The market value of their outstanding shares is at $10.5 million.
Wondering how the US markets performed one hour before the close of the markets on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.
Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session.
New Prostate Cancer Hope? Bayer-Funded Phase 2 Study To Test Combination Of RedHill's Opaganib And Bayer’s Darolutamide, To Overcome Androgen Resistance
RedHill Biopharma released study results showing opaganib's potential in treating Type 2 diabetes and obesity. The drug's ability to target sphingolipid metabolism could help prevent weight gain and improve glucose tolerance.
